Study shows low-dose chemo keeps cancer under control

February 24, 2016
Standard chemotherapeutic approaches rely on maximum tolerated doses (MTD) of chemotherapy, invariably selecting for the drug-resistant population by killing off not only drug-sensitive cancer cells but also healthy blood vessels and stromal cells, including native immune responders. The eco-evolutionary model proposed by Enriquez-Navas et al. is aimed at controlling tumor growth by maintaining an equilibrium between sensitive and resistant populations by means of low-dose frequent chemotherapy. The work demonstrates, in two different mouse xenograft models of breast carcinoma, that this approach can be more effective than the standard MTD approach in preventing disease progression and providing sustained control. Credit: Klement et al., Science Translational Medicine (2016)

Rather than try to wipe out cancer with powerful doses of chemotherapy, researchers said Wednesday an experimental approach using lower amounts of medication may work better to keep tumors under control.

The study was done on mice with breast , according to the report in Science Translational Medicine, and is part of a growing movement in oncology to explore alternatives to high-dose chemo and its often toxic side effects.

"Our results suggest that this adaptive therapeutic strategy... can result in prolonged progression-free survival in ," said the study, authored by Pedro Enriquez-Navas and colleagues at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.

Some researchers question the use of standard chemotherapy because it rarely wipes out cancer entirely, and leaves behind drug-resistant cells that can take over and lead to an explosion in tumor growth.

The new approach delivers continuous low-dose chemotherapy—in this case paclitaxel—that stabilizes the tumor by "maintaining a small population of drug-sensitive tumor cells to suppress the growth of resistant cells," said the study.

Standard doses of paclitaxel in mice shrunk breast tumors, but these tumors grew back once the treatment ended.

"Another treatment regimen that skips doses whenever the tumor shrunk also inevitably resulted in ," said the study.

"In contrast, adaptive therapy consisting of high initial drug doses followed by progressively lower doses as the responded was more effective in controlling than either standard therapy or dose skipping."

The study found that 60 to 80 percent of the mice treated by adaptive therapy could be "weaned off the drug completely without relapsing for an extended period of time."

More research is needed before the approach can be recommended for use in people.

However, the research offers "a very good possibility for future therapies," Giannoula Klement, of the Tufts University School of Medicine in Boston, wrote in an accompanying editorial.

"More and more oncologists are engaging some version of this approach."

Explore further: Some chemotherapy drugs may improve tumor response to immune checkpoint therapy

More information: "Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer," DOI: 10.1126/scitranslmed.aad7842

Read a press release here.

Related Stories

Cancer-killing proteins destroy tumor cells in bloodstream

January 12, 2016

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. ...

Recommended for you


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.